智通财经网·2025-08-28 01:55Core Viewpoint - Fosun Pharma's stock rose nearly 5% in early trading following the announcement of its mid-year results for 2025, which showed a mixed performance in revenue and profit [1] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 19.514 billion yuan, a year-on-year decrease of 4.63% [1] - Net profit attributable to shareholders was about 1.702 billion yuan, reflecting a year-on-year increase of 38.96% [1] - Basic earnings per share were reported at 0.64 yuan [1] - Revenue from innovative drugs showed robust growth, exceeding 4.3 billion yuan, which is a 14.26% increase compared to the same period last year [1] - The increase in profit was primarily due to gains from the sale of remaining equity in United Family Healthcare and other non-core assets [1] Strategic Developments - Fosun Pharma announced a licensing agreement with Sitala, granting rights for the development, production, and commercialization of FXS6837 and related products in regions outside of China [1] - The agreement allows Fosun Pharma or its designated affiliates to acquire shares in Sitala valued at 5 million USD at no cost [1] - This collaboration is expected to accelerate the clinical development and commercialization of licensed products globally, while also expanding the group's innovative product offerings overseas [1]